Existing drug could be repurposed to treat type 1 diabetes, study suggests

Type 1 diabetes is an autoimmune disease that causes the body's immune system to attack and destroy insulin-producing beta cells in the pancreas. Traditional management of type 1 diabetes has primarily involved replacing the missing insulin with injections which, though effective, can be expensive and burdensome.

Related Keywords

,Lily Ramsey ,Saraha Tersey ,Ernestos Nakayasu ,Raghu Mirmira ,Susanm Perkins ,Emilyk Sims ,Stephaniee Woerner ,Bobbie Jo Webb Robertson ,Lindaa Dimeglio ,Lori Blanchfield ,Fangqian Ouyang ,Susanne Cabrera ,Carmella Evans Molina ,Jacobr Enriquez ,Teresal Mastracci ,Lucyd Mastrandrea ,Eugenew Gerner ,Soumyadeep Sarkar ,Linda Dimeglio ,Batoul Hammoud ,Abhishek Kulkarni ,Raghavendra Mirmira ,Riley Children Health ,Iu School Of Medicine ,Indiana University ,University Of Chicago Medicine ,Diabetes Research Foundation ,Chicago Medicine ,Edwin Letzter Professor ,Indiana University School ,Riley Children ,Juvenile Diabetes Research Foundation ,Panbela Therapeutics ,African Sleeping Sickness ,Associate Professor ,Polyamine Biosynthesis Preserves ,Cell Function ,Cell Medicine Reports ,Audrey Hull ,Diabetes ,Type 1 Diabetes ,Autoimmune Disease ,Iochemistry ,Fell ,Children ,Clinical Trial ,Efficacy ,Endocrinologist ,Nzyme ,Immune System ,Insulin ,Medicine ,Metabolism ,Pancreas ,Ediatrics ,Research ,